Kymera Therapeutics’ (KYMR) Buy Rating Reaffirmed at Truist Financial

Truist Financial restated their buy rating on shares of Kymera Therapeutics (NASDAQ:KYMR) in a research report released on Friday morning, Benzinga reports. The brokerage currently has a $53.00 target price on the stock, down from their prior target price of $54.00.

KYMR has been the subject of several other research reports. Wells Fargo & Company lifted their price target on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Leerink Partners reissued an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Monday, September 9th. Morgan Stanley upped their target price on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 14th. Wolfe Research raised shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a research report on Monday, August 26th. Finally, B. Riley boosted their price target on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a report on Tuesday, July 9th. Four research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.15.

Kymera Therapeutics Trading Up 0.6 %

NASDAQ KYMR traded up $0.30 during trading hours on Friday, reaching $46.47. 432,609 shares of the company’s stock were exchanged, compared to its average volume of 597,398. The firm has a fifty day moving average of $47.04 and a 200-day moving average of $40.65. Kymera Therapeutics has a one year low of $9.60 and a one year high of $53.27. The stock has a market cap of $2.87 billion, a PE ratio of -19.20 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. The company had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. Kymera Therapeutics’s quarterly revenue was down 20.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.90) earnings per share. As a group, research analysts forecast that Kymera Therapeutics will post -2.85 EPS for the current year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $49.10, for a total transaction of $245,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Pamela Esposito sold 13,500 shares of the stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The disclosure for this sale can be found here. 15.82% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Several hedge funds have recently modified their holdings of the company. Values First Advisors Inc. bought a new position in Kymera Therapeutics in the third quarter valued at about $61,000. Mirae Asset Global Investments Co. Ltd. increased its position in Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after acquiring an additional 504 shares during the period. Comerica Bank raised its stake in shares of Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after acquiring an additional 400 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new position in shares of Kymera Therapeutics during the second quarter worth $139,000. Finally, Quest Partners LLC grew its stake in shares of Kymera Therapeutics by 1,402.0% in the second quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock worth $156,000 after purchasing an additional 4,865 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.